Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Burning Rock Biotech (BNR) Capital Leases (2019 - 2020)

Burning Rock Biotech has reported Capital Leases over the past 2 years, most recently at $116000.0 for Q3 2020.

For Q3 2020, Capital Leases changed N/A year-over-year to $116000.0; the TTM value through Sep 2020 reached $116000.0, changed N/A, while the annual FY2019 figure was $697491.0, N/A changed from the prior year.
Capital Leases for Q3 2020 was $116000.0 at Burning Rock Biotech, down from $307000.0 in the prior quarter.
Over five years, Capital Leases peaked at $683297.8 in Q4 2019 and troughed at $116000.0 in Q3 2020.